Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InTTercePT
2024-510703-11-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib in HER2-enriched breast cancer (HER2+), sponsored by Unicancer. Primary endpoint: 6-month progression-free survival rate. Planned start Mar 2024; status: authorised.
02
Drugs
tucatinib
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2024-510703-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510703-11-00.